Cargando…

Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series

Case series Patients: Male, 72-year-old • Female, 59-year-old • Female, 62-year-old Final Diagnosis: Multiple myeloma Symptoms: Anemia • hypercalcemia • lytic bone lesions Medication: Selinexor Clinical Procedure: — Specialty: Hematology OBJECTIVE: Unusual setting of medical care BACKGROUND: Numerou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Remaggi, Guillermina, Ochoa, Paola A., Garate, Gonzalo M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295189/ https://www.ncbi.nlm.nih.gov/pubmed/35834427 http://dx.doi.org/10.12659/AJCR.936505

Ejemplares similares

Selinexor for multiple myeloma
Publicado: (2022)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
por: Mateos, Maria V., et al.
Publicado: (2021)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
por: Dolph, Mike, et al.
Publicado: (2021)

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
por: Bassali, Jan, et al.
Publicado: (2020)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2020)

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
por: Dolph, Michael, et al.
Publicado: (2021)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials
por: Tao, Yali, et al.
Publicado: (2021)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
por: Du, Juan, et al.
Publicado: (2023)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
por: Prawitz, Thibaud, et al.
Publicado: (2021)

P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Niblock, James, et al.
Publicado: (2023)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Chari, Ajai, et al.
Publicado: (2023)

P920: EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA
por: Kuang, L., et al.
Publicado: (2022)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients
por: Nakamura, Hajime, et al.
Publicado: (2022)

Anaplastic Multiple Myeloma: Case Series and Literature Review
por: Wu, Jian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g7lnt49fecqqsug45ukqetgkio